GlassScriptPhysician profile
Paul D Volkert
NPI 1437143435
$17,490.27
in general payments reported to CMS, 2019-2025
24 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,128 · 2021: $2,298 · 2022: $655 · 2023: $1,843 · 2024: $285 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Travel and Lodging: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.24 |
| Travel and Lodging | $995.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,159.05 | 2019-2024 | Repatha |
| Medtronic Vascular, INC. | $2,008.84 | 2019-2020 | |
| Boston Scientific Corporation | $1,776.27 | 2019-2025 | Jetstream Sc, Opticross, Avvigo Guidance System |
| Medtronic, INC. | $1,303.23 | 2023 | Abre, Hawkone, Linq II |
| Cardiovascular Systems INC. | $593.14 | 2019-2022 | |
| Veryan Medical Incorporated | $336.56 | 2021-2024 | Biomimics 3d Vascular Stent System |
| Angiodynamics, INC. | $303.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $275.94 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $214.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.08 | 2019-2025 | Eliquis |
| Daiichi Sankyo INC. | $78.98 | 2020-2023 | Injectafer |
| Kestra Medical Technology Services, INC. | $52.44 | 2023 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $52.01 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $42.43 | 2019 | |
| Teleflex LLC | $32.83 | 2025 | Guideliner |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.47 | 2019 | |
| Surmodics, INC. | $22.32 | 2023 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce Thrombectomy |
| Biosense Webster, INC. | $21.93 | 2019 | |
| Terumo Medical Corporation | $21.63 | 2024 | Glidesheath Slender, Angio-Seal |
| Abbott Laboratories | $21.17 | 2025 | Esprit |
| Lundbeck LLC | $17.75 | 2019 | |
| Becton, Dickinson and Company | $14.93 | 2023 | Lifestream |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.47 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Volkert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.